Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2022 vs. Q1 2022
How the institutions holding Intra-Cellular Therapies, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 241 | 2 | 266 | +27 |
| Shares | 80.8M | 282.8K | 81.5M | +945.5K (+1.2%) |
| Value | $4.94B | $17.3M | $4.65B | −$269.1M (−5.5%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (46)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (19)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Marshall Wace, LLP | 2,519,764 | $154.2M |
| Employees Retirement System of Texas | 97,500 | $5.97M |
| Campbell & CO Investment Adviser LLC | 37,863 | $2.32M |
| Balyasny Asset Management LLC | 31,967 | $1.96M |
| Graypoint LLC | 26,436 | $1.62M |
| Brookfield Asset Management Inc. | 25,540 | $1.56M |
| Virtue Capital Management, LLC | 18,232 | $1.12M |
| Virtu Financial LLC | 17,143 | $1.05M |
| Caxton Associates LP | 14,591 | $893.0K |
| Twinbeech Capital LP | 12,317 | $754.0K |
| Maven Securities LTD | 8,919 | $546.0K |
| Cambridge Investment Research Advisors, Inc. | 5,701 | $349.0K |
| Beacon Pointe Advisors, LLC | 3,518 | $215.0K |
| Shikiar Asset Management Inc | 3,500 | $214.0K |
| Cutler Group LP | 1,786 | $109.0K |
| Aquatic Capital Management LLC | 1,200 | $73.0K |
| TCWP LLC | 37 | $2.00K |
| TD Waterhouse Canada Inc. | 24 | $1.50K |
| Ellevest, Inc. | 16 | $1.00K |
Not filed for Q2 2022 yet (2)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 269,677 | $16.5M |
| Amalgamated Financial Corp. | 13,172 | $806.0K |